Angiochem's ANG1005 demonstrates safety and efficacy in Phase 1/2 brain cancer studies

October 18, 2009

ANG1005 Crosses the Blood-Brain Barrier to Reduce Tumor Size and is Effective in Resistant Tumors.

Angiochem's EPiC platform validated in humans: EPiC Drugs Cross Blood-Brain Barrier.

Montreal, Canada, and Chicago, IL, October 18, 2009. Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. These data, which validates in humans Angiochem's peptide-based platform technology (EPiC), were presented at the Society for Neuroscience Annual Meeting in Chicago on October 18, 2009.

Read the full article

Retour